

## DAFTAR PUSTAKA

Globocan 2020. (2021). The Global Cancer Observatory, 1-2.

Setiawan, Syahru & Hardianti, Mardiah & Anggorowati, Nungki & Probowati, Wiwiek. (2021). Association of AID and MUM1 by Immunohistochemistry in Diffuse Large B-Cell Lymphoma. The Indonesian Biomedical Journal.

<http://dx.doi.org/10.18585/inabj.v13i1.1421>

Anggorowati, N., Yano, Y., Heriyanto, D. S., Rinonce, H. T., Utsumi, T., Mulya, D. P., Subronto, Y. W., & Hayashi, Y. (2012). Clinical and virological characteristics of hepatitis B or C virus co-infection with HIV in Indonesian patients. *Journal of medical virology*, 84(6), 857–865. <https://doi.org/10.1002/jmv.23293>.

Brody, R.I., Eng, S.P., Melamed, J., Mizrachi, H., Schneider, R.J., Tobías, H.M., Teperman, L.W., & Theise, N.D. (1998). Immunohistochemical detection of hepatitis C antigen by monoclonal antibody TORDJI-22 compared with PCR viral detection. *American journal of clinical pathology*, 1101, 32-7.

<https://doi.org/10.1093/ajcp/110.1.32>

Canioni, D., Michot, J. M., Rabiega, P., Molina, T. J., Charlotte, F., Lazure, T., Davi, F., Settegrana, C., Berger, F., Alric, L., Cacoub, P., Terrier, B., Suarez, F., Sibon, D., Dupuis, J., Feray, C., Tilly, H., Pol, S., Deau Fischer, B., Roulland, S., ... national ANRS HC13 LymphoC study (2016). In Situ Hepatitis C NS3 Protein Detection Is Associated with High Grade Features in Hepatitis C-Associated B-Cell Non-Hodgkin Lymphomas. *PloS one*, 11(6), e0156384.

<https://doi.org/10.1371/journal.pone.0156384>.

Couronné, L., Bachy, E., Roulland, S., Nadel, B., Davi, F., Armand, M., Canioni, D., Michot, J. M., Visco, C., Arcaini, L., Besson, C., & Hermine, O. (2018). From hepatitis C virus infection to B-cell lymphoma. *Annals of oncology: official journal of the European Society for Medical Oncology*, 29(1), 92–100.

<https://doi.org/10.1093/annonc/mdx635>

Dal Maso, L., & Franceschi, S. (2006). Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies. *Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*, 15(11), 2078-2085. <https://doi.org/10.1158/1055-9965.EPI-06-0308>.

- Defrancesco, I., Zerbi, C., Rattotti, S., Merli, M., Bruno, R., Paulli, M., & Arcaini, L. (2020). HCV infection and non-Hodgkin lymphomas: an evolving story. *Clinical and experimental medicine*, 20(3), 321–328. <https://doi.org/10.1007/s10238-020-00615-6>.
- Deutsch, Y. E., Tadmor, T., Podack, E. R., & Rosenblatt, J. D. (2011). CD30: an important new target in hematologic malignancies. *Leukemia & lymphoma*, 52(9), 1641–1654. <https://doi.org/10.3109/10428194.2011.574761>
- Diumenjo, Maria & Abriata, Graciela & Forman, David & Sierra, Monica. (2016). The burden of non-Hodgkin lymphoma in Central and South America. *Cancer epidemiology*. 44 Suppl 1. S168-S177. <https://doi.org/10.1016/j.canep.2016.05.008>
- Flores-Chávez, A., Carrion, J. A., Forns, X., & Ramos-Casals, M. (2017). Extrahepatic manifestations associated with Chronic Hepatitis C Virus Infection. *Revista espanola de sanidad penitenciaria*, 19(3), 87–97. <https://doi.org/10.4321/S1575-06202017000300004>.
- Forghieri, F., Luppi, M., Barozzi, P., Maffei, R., Potenza, L., Narni, F., & Marasca, R. (2012). Pathogenetic mechanisms of hepatitis C virus-induced B-cell lymphomagenesis. *Clinical & developmental immunology*, 2012, 807351. <https://doi.org/10.1155/2012/807351>.
- Foschi, F. G., Gramenzi, A., Castelli, E., Cursaro, C., Pagani, S., Margotti, M., D'Errico, A., Andreone, P., Stefanini, G. F., & Bernardi, M. (2000). Soluble CD30 serum level in HCV-positive chronic active hepatitis: A surrogate marker of disease activity?. *Cytokine*, 12(6), 815–818. <https://doi.org/10.1006/cyto.1999.0653>.
- Gong, Q. X., Lu, T. X., Liu, C., Wang, Z., Liang, J. H., Xu, W., Li, J. Y., Zhang, Z. H., & Chen, Q. (2015). Prevalence and clinicopathologic features of CD30-positive de novo diffuse large B-cell lymphoma in Chinese patients: a retrospective study of 232 cases. *International journal of clinical and experimental pathology*, 8(12), 15825–15835. <http://www.ncbi.nlm.nih.gov/pmc/articles/pmc4730066/>
- Gong, Q. X., Wang, Z., Liu, C., Li, X., Lu, T. X., Liang, J. H., Xu, W., Li, J. Y., & Zhang, Z. H. (2018). CD30 expression and its correlation with MYC and BCL2 in de novo diffuse large B-cell lymphoma. *Journal of clinical pathology*, 71(9), 795–801. <https://doi.org/10.1136/jclinpath-2018-205039>.
- Gustaf Hedström, Stefan Peterson, Mattias Berglund, Mats Jerkeman, Gunilla Enblad & on behalf of the Swedish Lymphoma Study Group (2015) Male

gender is an adverse risk factor only in young patients with diffuse large B-cell lymphoma – a Swedish population-based study, *Acta Oncologica*, 54:6, 924-932. <https://doi.org/10.3109/0284186x.2015.1026455>

Horesh, N., & Horowitz, N. A. (2014). Does gender matter in non-hodgkin lymphoma? Differences in epidemiology, clinical behavior, and therapy. *Rambam Maimonides medical journal*, 5(4), e0038. <https://doi.org/10.5041/RMMJ.10172>

Julianty, P. F. ., Ham, M. F., Kusmardi, K., & Harahap, A. S. (2020). CD30 Expression in Germinal Center B-cell-like and non-Germinal Center B-cell-like Subtypes of Diffuse Large B-cell Lymphoma. *Open Access Macedonian Journal of Medical Sciences*, 8(B), 375–380. <https://doi.org/10.3889/oamjms.2020.4645>.

Yi, J. H., Kim, S. J., & Kim, W. S. (2017). Brentuximab vedotin: clinical updates and practical guidance. *Blood research*, 52(4), 243–253. <https://doi.org/10.5045/br.2017.52.4.243>.

Li, S., Young, K. H., & Medeiros, L. J. (2018). Diffuse large B-cell lymphoma. *Pathology*, 50(1), 74–87. <https://doi.org/10.1016/j.pathol.2017.09.006>.

Lohmann V. (2013). Hepatitis C virus RNA replication. *Current topics in microbiology and immunology*, 369, 167–198. [https://doi.org/10.1007/978-3-642-27340-7\\_7](https://doi.org/10.1007/978-3-642-27340-7_7).

Martyak, Lenna & Yeganeh, Melina & Saab, Sammy. (2009). Hepatitis C and Lymphoproliferative Disorders: From Mixed Cryoglobulinemia to Non-Hodgkin's Lymphoma. *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*. 7.900-5. [https://www.cghjournal.org/article/S1542-3565\(09\)00313-9/pdf](https://www.cghjournal.org/article/S1542-3565(09)00313-9/pdf)

Marascio, N., Liberto, M.C., Barreca, G.S. *et al.* Update on epidemiology of HCV in Italy: focus on the Calabria Region. *BMC Infect Dis* 14, S2 (2014). <https://doi.org/10.1186/1471-2334-14-S5-S2>

Morais-Perdigão, A. L., Rodrigues-Fernandes, C. I., Araújo, G. R., Soares, C. D., de Andrade, B., Martins, M. D., Vargas, P. A., Pontes, H., Pires, F. R., Burbano, R., & Fonseca, F. P. (2021). CD30 Expression in Oral and Oropharyngeal Diffuse Large B Cell Lymphoma, not Otherwise Specified. *Head and neck pathology*, 10.1007/s12105-021-01387-5. Advance online publication. <https://doi.org/10.1007/s12105-021-013875>.

- Pellicelli, A. M., Marignani, M., Zoli, V., Romano, M., Morrone, A., Nosotti, L., Barbaro, G., Picardi, A., Gentilucci, U. V., Remotti, D., D'Ambrosio, C., Furlan, C., Mecenate, F., Mazzoni, E., Majolino, I., Villani, R., Andreoli, A., & Barbarini, G. (2011). Hepatitis C virus related B cell subtypes in non Hodgkin's lymphoma. *World journal of hepatology*, 3(11), 278–284. <https://doi.org/10.4254/wjh.v3.i11.278>.
- Reiser, M., Marousis, C. G., Nelson, D. R., Lauer, G., González-Peralta, R. P., Davis, G. L., & Lau, J. Y. (1997). Serum interleukin 4 and interleukin 10 levels in patients with chronic hepatitis C virus infection. *Journal of hepatology*, 26(3), 471–478. [https://doi.org/10.1016/s01688278\(97\)80409-6](https://doi.org/10.1016/s01688278(97)80409-6).
- Reksodiputro, Ary. (2015). Multicentre Epidemiology and Survival Study of B Cell Non Hodgkin Lymphoma Patients In Indonesia. *Journal of Blood Disorders & Transfusion*. 06. <http://dx.doi.org/10.4172/2155-9864.1000257>
- Rodrigues-Fernandes, C.I., Abreu, L.G., Radhakrishnan, R., Perez, D., Amaral-Silva, G.K., Gondak, R.O., Rahimi, S., Brennan, P.A., Fonseca, F.P., & Vargas, P.A. (2021). Prognostic significance of CD30 expression in diffuse large B-cell lymphoma: A systematic review with meta-analysis. *Journal of oral pathology & medicine: official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology*, 50(6), 587–593. <https://doi.org/10.1111/jop.13208>.
- Santoso, Maria & Hardianti, Mardiah & Indrawati, Indrawati & Anggorowati, Nungki. (2020). CD30 Expression and Its Correlation with Clinicopathologic Features in Indonesian Diffuse Large B-Cell Lymphoma. *Asian Pacific Journal of Cancer Biology*. 5.107-113. <http://dx.doi.org/10.31557/apjcb.2020.5.3.107-113>
- Mihăilă R. G. (2016). Hepatitis C virus - associated B cell non-Hodgkin's lymphoma. *World journal of gastroenterology*, 22(27), 6214–6223. <https://doi.org/10.3748/wjg.v22.i27.6214>.
- Jukić, L. V. , & Kralj, D. (2017). Extrahepatic Manifestations of Hepatitis C Virus Infection. In M. Smolic, A. Vcev, & G. Y. Wu (Eds.), *Update on Hepatitis C*. IntechOpen. <https://doi.org/10.5772/intechopen.70728>.
- Visco, C., & Finotto, S. (2014). Hepatitis C virus and diffuse large B-cell lymphoma: Pathogenesis, behavior and treatment. *World journal of gastroenterology*, 20(32), 11054–11061. <https://doi.org/10.3748/wjg.v20.i32.11054>.

- Vannata, B., Arcaini, L., Zucca, E., 2016. Hepatitis C virus-associated B-cell non- Hodgkin's lymphomas: what do we know? *Therapeutic Advances in Hematology* 7, 94–107. <https://doi.org/10.1177/2040620715623924>
- Wang, X. J., Seegmiller, A. C., Reddy, N. M., & Li, S. (2016). CD30 expression and its correlation with MYC rearrangement in de novo diffuse large B-cell lymphoma. *European journal of haematology*, 97(1), 39–47. <https://doi.org/10.1111/ejh.12680>.
- Xu, M. L., Gabali, A., Hsi, E. D., Fedoriw, Y., Vij, K., Salama, M. E., Ramchandren, R., O'Malley, D., Wick, M. R., Battistella, M., & Gru, A. A. (2020). Practical Approaches on CD30 Detection and Reporting in Lymphoma Diagnosis. *The American journal of surgical pathology*, 44(2), e1–e14. <https://doi.org/10.1097/PAS.0000000000001368>.
- Yazici, O., Sendur, M. A., & Aksoy, S. (2014). Hepatitis C virus reactivation in cancer patients in the era of targeted therapies. *World journal of gastroenterology*, 20(22), 6716–6724. <https://doi.org/10.3748/wjg.v20.i22.6716>
- Koens, L., van de Ven, P. M., Hijmering, N. J., Kersten, M. J., Diepstra, A., Chamuleau, M., & de Jong, D. (2018). Interobserver variation in CD30 immunohistochemistry interpretation; consequences for patient selection for targeted treatment. *Histopathology*, 73(3), 473–482. <https://doi.org/10.1111/his.13647>